Shuiying Hu

List of Publications by Year in Descending Order

71 papers	2,845 citations	31 h-index	53 g-index
78 ext. papers	3,315 ext. citations	6.8 avg, IF	4.72 L-index

#	Paper	IF	Citations
71	Targeting drug transporters to prevent chemotherapy-induced peripheral neuropathy. *Molecular and Cellular Oncology*, **2021**, 8, 1838863	1.2	1
70	Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1. *Frontiers in Pharmacology*, **2021**, 12, 644342	5.6	3
69	Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2021**, 1168, 122591	3.2	1
68	Contribution of membrane transporters to chemotherapy-induced cardiotoxicity. *Basic and Clinical Pharmacology and Toxicology*, **2021**,	3.1	1
67	Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy. *Clinical and Translational Science*, **2021**, 14, 460-467	4.9	9
66	DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. *Clinical and Translational Science*, **2021**, 14, 137-142	4.9	6
65	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	7
64	Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. *Cancers*, **2021**, 13,	6.6	11
63	Regulation of OATP1B1 Function by Tyrosine Kinase-mediated Phosphorylation. *Clinical Cancer Research*, **2021**, 27, 4301-4310	12.9	4
62	Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation. *Molecules* , **2021**, 26,	4.8	1
61	Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy. *Nature Communications*, **2020**, 11, 972	17.4	49
60	Role of transporters in toxicity induced by anticancer drugs. *Expert Opinion on Drug Metabolism and Toxicology*, **2020**, 16, 493-506	5.5	6
59	Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions. *Drug Metabolism and Disposition*, **2020**, 48, 419-425	4	15
58	Abstract 14035: Renal Tubular Secretion and Cardiac Distribution of Dofetilide is Dependent on MATE1 Function. *Circulation*, **2020**, 142,	16.7	1
57	Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. *Journal of Clinical Investigation*, **2020**, 130, 4601-4606	15.9	22
56	A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.. *Journal of Clinical Oncology*, **2020**, 38, TPS12125-TPS12125	2.2	3
55	A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer.. *Journal of Clinical Oncology*, **2020**, 38, TPS12128-TPS12128	2.2	1

54	Role of transporters and S100A8/A9 in paclitaxel-induced peripheral neuropathy. *FASEB Journal*, **2020**, 34, 1-1	0.9	
53	Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions. *Reviews of Physiology, Biochemistry and Pharmacology*, **2020**, 1	2.9	4
52	Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 227-237	6.1	16
51	Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. *Clinical Cancer Research*, **2019**, 25, 6295-6301	12.9	35
50	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. *Nature Communications*, **2019**, 10, 2189	17.4	9
49	Development and validation of a UPLC-MS/MS analytical method for dofetilide in mouse plasma and urine, and its application to pharmacokinetic study. *Journal of Pharmaceutical and Biomedical Analysis*, **2019**, 172, 183-188	3.5	0
48	Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy. *Materials Science and Engineering C*, **2019**, 102, 113-123	8.3	17
47	Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice. *Clinical and Translational Science*, **2019**, 12, 400-407	4.9	7
46	Predicting Paclitaxel Disposition in Humans With Whole-Body Physiologically-Based Pharmacokinetic Modeling. *CPT: Pharmacometrics and Systems Pharmacology*, **2019**, 8, 931-939	4.5	3
45	Epigenetic Regulation of OCTN1-mediated Cytarabine Transport in Acute Myeloid Leukemia. *FASEB Journal*, **2019**, 33, 675.2	0.9	
44	Role of OATP2B1 in Drug Absorption and Drug-Drug Interactions. *FASEB Journal*, **2019**, 33, 507.7	0.9	
43	Genetic and Pharmacological Inhibition of OCT2 Protects Rats against Oxaliplatin-Induced Peripheral Neuropathy. *FASEB Journal*, **2019**, 33, 813.9	0.9	1
42	Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice. *Pharmacology Research and Perspectives*, **2019**, 7, e00534	3.1	6
41	Drug transporters and anthracycline-induced cardiotoxicity. *Pharmacogenomics*, **2018**, 19, 883-888	2.6	10
40	Strategies to Reduce Solute Carrier-Mediated Toxicity. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 799-802	6.1	4
39	OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. *Journal of Clinical Investigation*, **2018**, 128, 816-825	15.9	38
38	Murine Pharmacokinetic Studies. *Bio-protocol*, **2018**, 8,	0.9	11
37	Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2018**, 1090, 43-51	3.2	8

36	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. *Cancer Research*, **2017**, 77, 2102-2111	10.1	30
35	A phosphotyrosine switch regulates organic cation transporters. *Nature Communications*, **2016**, 7, 10880	17.4	74
34	Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. *Clinical Pharmacology and Therapeutics*, **2016**, 99, 651-60	6.1	19
33	Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. *Cancer Research*, **2016**, 76, 117-26	10.1	33
32	Evaluation of artemisinins for the treatment of acute myeloid leukemia. *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 1231-43	3.5	30
31	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. *Cancer Research*, **2015**, 75, 2729-36	10.1	46
30	Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 5231-6	11.5	51
29	Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. *British Journal of Cancer*, **2014**, 110, 894-8	8.7	38
28	Influence of drug formulation on OATP1B-mediated transport of paclitaxel. *Cancer Research*, **2014**, 74, 3137-45	10.1	36
27	Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). *Clinical Cancer Research*, **2014**, 20, 985-94	12.9	45
26	Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. *Clinical Cancer Research*, **2013**, 19, 236-46	12.9	56
25	Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. *Clinical Pharmacology and Therapeutics*, **2013**, 94, 585-92	6.1	46
24	Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. *Molecular Cancer Therapeutics*, **2013**, 12, 1537-44	6.1	38
23	Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. *Clinical Cancer Research*, **2013**, 19, 4359-4370	12.9	34
22	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. *Clinical Cancer Research*, **2013**, 19, 1458-66	12.9	109
21	Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. *Blood*, **2013**, 122, 3607-15	2.2	140
20	TAK1 is a Regulator of Sorafenib-induced Keratinocyte Toxicity. *FASEB Journal*, **2013**, 27, 657.1	0.9	
19	OATP1B1 polymorphism as a determinant of erythromycin disposition. *Clinical Pharmacology and Therapeutics*, **2012**, 92, 642-50	6.1	21

18	Inhibition of OCTN2-mediated transport of carnitine by etoposide. *Molecular Cancer Therapeutics*, **2012**, 11, 921-9	6.1	46
17	Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. *Clinical Cancer Research*, **2012**, 18, 4433-40	12.9	70
16	Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. *Journal of the National Cancer Institute*, **2011**, 103, 893-905	9.7	45
15	Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. *Clinical Cancer Research*, **2009**, 15, 6062-9	12.9	132
14	Pharmacokinetic considerations for new targeted therapies. *Clinical Pharmacology and Therapeutics* , **2009**, 85, 208-11	6.1	26
13	Pharmacogenetic pathway analysis of docetaxel elimination. *Clinical Pharmacology and Therapeutics*, **2009**, 85, 155-63	6.1	135
12	Interaction of imatinib with human organic ion carriers. *Clinical Cancer Research*, **2008**, 14, 3141-8	12.9	176
11	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. *Molecular Cancer Therapeutics*, **2008**, 7, 1110-20	6.1	40
10	Role of mitochondria in silica-induced apoptosis of alveolar macrophages: inhibition of apoptosis by rhodamine 6G and N-acetyl-L-cysteine. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2007**, 70, 1403-15	3.2	14
9	Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. *Clinical Cancer Research*, **2007**, 13, 1341-9	12.9	141
8	Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. *Clinical Cancer Research*, **2007**, 13, 1161-70	12.9	317
7	Preclinical Evaluation of Sorafenib in Combination with Cytarabine and Clofarabine in Acute Myeloid Leukemia (AML).. *Blood*, **2007**, 110, 4202-4202	2.2	
6	Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. *International Journal of Cancer*, **2006**, 119, 2322-9	7.5	140
5	Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 98-104	5.6	38
4	Silica-induced apoptosis in alveolar macrophages: evidence of in vivo thiol depletion and the activation of mitochondrial pathway. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2006**, 69, 1261-84	3.2	37
3	Phosphatidylinositol 3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells. *Journal of Immunology*, **2006**, 176, 6785-93	5.3	57
2	Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 4688-93	5.6	171
1	High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 5265-9	5.6	101